Partner Headlines - ALKS

  1. 3 Biotech ETFs Rally On Merger News

    Benzinga
  2. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga
  3. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  4. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  5. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  6. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  7. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  8. Alkermes' drug passes trial

    IBD
  9. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  10. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  11. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  12. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  13. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  14. Benzinga's Volume Movers

    Benzinga
  15. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  16. Morning Market Movers

    Benzinga
  17. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  18. Benzinga's Top Initiations

    Benzinga
  19. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  20. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  21. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  22. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  23. Stocks End Short Week With Big Losses

    IBD
  24. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  25. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  26. Ireland Home To Several Fast Growing Health Care Names

    IBD
  27. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  28. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  29. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  30. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  31. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  32. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  33. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  34. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  35. Alkermes

    IBD
  36. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  37. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  38. Alkermes

    IBD
  39. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  40. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  41. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  42. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  43. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  44. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  45. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  46. Stocks Pare Early Losses, End With Modest Declines

    IBD
  47. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  48. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  49. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  50. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  51. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  52. Dow Leads Market Higher As Volume Swells

    IBD
  53. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  54. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  55. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  56. Stocks Tumble On Disappointing Earnings Reports

    IBD
  57. Why Cisco, Google And Apple All Became Big Winners

    IBD
  58. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  59. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  60. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  61. Alkermes Writes New Prescription For Growth

    IBD
  62. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  63. Health Care Sector Wrap

    FoxBusiness
  64. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  65. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  66. Elan

    IBD
  67. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  68. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  69. Market Roundup

    Benzinga
  70. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  71. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  72. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  73. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  74. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  75. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  76. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  77. Benzinga's Top Pre-Market Gainers

    Benzinga
  78. UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

    Benzinga
  79. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  80. Benzinga's Volume Gainers

    Benzinga
  81. CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous ...

    Benzinga
  82. Feuerstein: Alkermes CEO says Bydureon Drug will be Approved ...

    Benzinga
  83. Top-Performing Fund Managers Tap Retail, Food Stocks

    IBD
  84. Positive Data Lifts Stocks in Early Trading

    MarketIntelligenceCenter
  85. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
Trading Center